Claims for Patent: 9,730,946

Summary for Patent: 9,730,946

Title:	Use of vanadium compounds to accelerate bone healing
Abstract:	This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.
Inventor(s):	Lin; Sheldon S. (Chatham, NJ), Paglia; David N. (New Britain, CT), O\'Connor; James P. (Fanwood, NJ), Breitbart; Eric (South Orange, NJ), Benevenia; Joseph (Montclair, NJ)
Assignee:	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (New Brunswick, NJ)
Application Number:	14/566,237
Patent Claims:	1. A bone injury treatment kit comprising a composition sterilized for in vivo bone administration comprising an insulin-mimetic vanadium compound and a pharmaceutically suitable carrier for localized bone delivery, wherein said composition is packaged in a container for localized administration of said vanadium compound to a patient in need thereof. 2. The bone injury treatment kit of claim 1, wherein said vanadium compound is selected from the group consisting of vanadyl acetylacetonate (VAC), vanadyl sulfate (VS), vanadyl 3-ethylacetylacetonate (VET), and bis(maholato)oxovanadium (BMOV). 3. The bone injury treatment kit of claim 1, wherein said vanadium compound is vanadyl acetylacetonate (VAC). 4. The bone injury treatment kit of claim 1, further comprising a bone graft biocomposite. 5. The bone injury treatment kit of claim 1, further comprising a bioactive agent for treating injured bone tissue. 6. The bone injury treatment kit of claim 4, wherein the bone graft biocomposite is selected from the group consisting of allografts, xenografts, alloplastic grafts and synthetic grafts. 7. The bone injury treatment kit of claim 5, wherein said bioactive agent is selected from the group consisting of peptide growth factors, anti-inflammatory factors, pro-inflammatory factors, inhibitors of apoptosis, MMP inhibitors and bone catabolic antagonists. 8. The bone injury treatment kit of claim 7, wherein said peptide growth factor is selected from the group consisting of IGF (1, 2), PDGF (AA, AB, BB), BMPs, FGF (1-20), TGF-beta (1-3), aFGF, bFGF, EGF, VEGF, parathyroid hormone (PTH), and parathyroid hormone-related protein (PTHrP). 9. The bone injury treatment kit of claim 7, wherein said anti-inflammatory factor is selected from the group consisting of anti-TNF.alpha., soluble TNF receptors, IL1ra, soluble IL1 receptors, IL4, IL-10, and IL-13. 10. The bone injury treatment kit of claim 7, wherein said bone catabolic antagonist is selected from the group consisting of bisphosphonates, osteoprotegerin, and statins. 11. The bone injury treatment kit of claim 1, wherein the composition is formulated for a human patient. 12. The bone injury treatment kit of claim 11, wherein the composition is formulated for a non-diabetic human patient. 13. The bone injury treatment kit of claim 1, wherein the composition is formulated for administration to an animal selected from the group consisting of horses, dogs and cats.

Details for Patent 9,730,946

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2030-01-15